SK69799A3 - Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists - Google Patents

Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists Download PDF

Info

Publication number
SK69799A3
SK69799A3 SK697-99A SK69799A SK69799A3 SK 69799 A3 SK69799 A3 SK 69799A3 SK 69799 A SK69799 A SK 69799A SK 69799 A3 SK69799 A3 SK 69799A3
Authority
SK
Slovakia
Prior art keywords
gndnl
nothing
compounds
guanidine
unsubstituted
Prior art date
Application number
SK697-99A
Other languages
English (en)
Slovak (sk)
Inventor
Thomas Lee Cupps
Sophie Eva Bogdan
Raymond Todd Henry
Russell James Sheldon
William Lee Seibel
Jeffrey Joseph Ares
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SK69799A3 publication Critical patent/SK69799A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK697-99A 1996-11-25 1997-11-21 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists SK69799A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3202396P 1996-11-25 1996-11-25
PCT/US1997/020802 WO1998023596A1 (en) 1996-11-25 1997-11-21 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
SK69799A3 true SK69799A3 (en) 2000-06-12

Family

ID=21862692

Family Applications (1)

Application Number Title Priority Date Filing Date
SK697-99A SK69799A3 (en) 1996-11-25 1997-11-21 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

Country Status (25)

Country Link
US (3) US6225331B1 (no)
EP (1) EP0944604B1 (no)
JP (1) JP2001506600A (no)
KR (1) KR20000069131A (no)
CN (1) CN1104422C (no)
AR (1) AR009145A1 (no)
AT (1) ATE286885T1 (no)
AU (1) AU730369B2 (no)
BR (1) BR9713536A (no)
CA (1) CA2272640C (no)
CO (1) CO4910148A1 (no)
CZ (1) CZ184099A3 (no)
DE (1) DE69732244T2 (no)
ES (1) ES2236833T3 (no)
HU (1) HUP0000312A3 (no)
ID (1) ID23857A (no)
IL (1) IL130077A0 (no)
NO (1) NO313912B1 (no)
NZ (1) NZ336010A (no)
PE (1) PE16399A1 (no)
RU (1) RU2194700C2 (no)
SK (1) SK69799A3 (no)
TR (1) TR199901468T2 (no)
WO (1) WO1998023596A1 (no)
ZA (1) ZA9710578B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732244T2 (de) 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
MXPA03001437A (es) * 2000-09-08 2005-06-03 Warner Lambert Co Prevencion de sinusitis aguda y crisis sinusal.
EP1385823B1 (en) * 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030229025A1 (en) * 2002-02-25 2003-12-11 Chiron Corporation Intranasal administration of MC4-R agonists
EP1551834B1 (en) * 2002-05-23 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Substituted quinazolinone compounds
WO2004112793A1 (en) * 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
CA2545601A1 (en) * 2003-11-19 2005-06-09 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
US7375219B2 (en) * 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US8173813B2 (en) * 2007-03-23 2012-05-08 Neuraxon, Inc. Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
WO2010065547A1 (en) * 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
GB0919889D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CN112047947A (zh) * 2020-10-13 2020-12-08 石药集团新诺威制药股份有限公司 一种茶碱的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908013A (en) 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3947455A (en) 1974-04-15 1976-03-30 Armour Pharmaceutical Company 5'-(8'-Hydroxyquinolyl)guanidine compounds
US4000279A (en) 1974-10-29 1976-12-28 Armour Pharmaceutical Company Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
PT735877E (pt) * 1993-12-17 2000-12-29 Procter & Gamble Compostos de 6-(2-imidazolinilamino)quinoxalina uteis como agonistas do receptor alfa-2 adrenergico
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
DE69732244T2 (de) 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
ES2236833T3 (es) 2005-07-16
KR20000069131A (ko) 2000-11-25
US20020128481A1 (en) 2002-09-12
AU5438198A (en) 1998-06-22
US20010000345A1 (en) 2001-04-19
JP2001506600A (ja) 2001-05-22
RU2194700C2 (ru) 2002-12-20
AU730369B2 (en) 2001-03-08
US6391878B2 (en) 2002-05-21
NO992498D0 (no) 1999-05-25
BR9713536A (pt) 2000-11-07
DE69732244T2 (de) 2006-06-29
NO313912B1 (no) 2002-12-23
TR199901468T2 (xx) 1999-10-21
WO1998023596A1 (en) 1998-06-04
IL130077A0 (en) 2000-02-29
DE69732244D1 (de) 2005-02-17
NZ336010A (en) 2001-05-25
ATE286885T1 (de) 2005-01-15
CN1104422C (zh) 2003-04-02
US6225331B1 (en) 2001-05-01
ZA9710578B (en) 1998-06-25
ID23857A (id) 2000-05-25
AR009145A1 (es) 2000-03-08
CO4910148A1 (es) 2000-04-24
CZ184099A3 (cs) 1999-11-17
EP0944604B1 (en) 2005-01-12
PE16399A1 (es) 1999-03-12
NO992498L (no) 1999-07-26
HUP0000312A2 (hu) 2000-09-28
CN1242006A (zh) 2000-01-19
CA2272640A1 (en) 1998-06-04
CA2272640C (en) 2003-07-08
HUP0000312A3 (en) 2001-12-28
EP0944604A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
SK69799A3 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
KR100395356B1 (ko) 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노인돌 화합물
US5916900A (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US6110952A (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US6306877B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
EP0944601B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
SK69699A3 (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
CA2285610A1 (en) 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 adrenoceptor agonists
MXPA99004843A (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists